Inhibition of IGF-1R and lipoxygenase by nordihydroguaiaretic acid (NDGA) analogs

Department of Chemistry and Biochemistry, San Francisco State University, San Francisco, California, United States
Bioorganic & Medicinal Chemistry Letters (Impact Factor: 2.33). 08/2007; 17(14):4026-9. DOI: 10.1016/j.bmcl.2007.04.092
Source: PubMed

ABSTRACT Herein, we pursue the hypothesis that the structure of nordihydroguaiaretic acid (NDGA) can be refined for selective potency against the insulin-like growth factor 1 receptor (IGF-1R) as a potential therapeutic target for breast cancer while diminishing its action against other cellular targets. Thus, a set of NDGA analogs (7a-7h) was prepared and examined for inhibitory potency against IGF-1R kinase and an alternative target, 15-lipoxygenase (15 LOX). The anti-cancer effects of these compounds were determined by their ability to inhibit IGF-1 mediated cell growth of MCF-7 breast cancer cells. The design of the analogs was based upon a cursory Topliss approach in which one of NDGA's aromatic rings was modified with various substituents. Structural modification of one of the two catechol rings of NDGA was found to have little effect upon the inhibitory potency against both kinase activity of the IGF-1R and IGF-1 mediated cell growth of MCF-7 cells. 15-LOX was found to be most sensitive to structural modifications of NDGA. From the limited series of NDGA analogs examined, the compound that exhibited the greatest selectivity for IGF-1 mediated growth compared to 15-LOX inhibition was a cyclic analog 7h with a framework similar to a natural product isolated from Larrea divaricata. The results for 7h are significant because while NDGA displays biological promiscuity, 7h exhibits greater specificity toward the breast cancer target IGF-1R with that added benefit of possessing a 10-fold weaker potency against 15-LOX, an enzyme which has a purported tumor suppressing role in breast cancer. With increased specificity and potency, 7h may serve as a new lead in developing novel therapeutic agents for breast cancer.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Accumulating evidence suggests that high expression of FGFR1 is closely related to the development of lung cancer especially in non-small cell lung cancers (NSCLC), to which non-ATP competitive inhibitors represent an effective therapeutical approach due to their good specificity. Herein, a series of NDGA analogues with the framework of bisaryl-1,4-dien-3-one as novel FGFR1 inhibitors have been designed and screened. Among them Aea4 and Aea25 showed strong FGFR1`inhibition and high selectivity over other receptor kinases. The kinase inhibitory assay in different ATP concentrations and computer-assistant molecular docking showed that the FGFR1 inhibition mode of both Aea4 and Aea25 was non-ATP-competitive. The in vitro and in vivo study on anticancer efficacy of Aea4 and Aea25 against non-small cell lung cancer involves inhibition of cell proliferation, apoptosis induction and cell cycle arrest with no toxicity. Thus, these two novel non-ATP competitive inhibitors derived from NDGA may have a great therapeutic potential in the treatment of NSCLC. This work also provides a structural lead for the design of new non-ATP-competitive FGFR1 inhibitors.
    Oncotarget 06/2014; 5(12). · 6.63 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The semi-synthetic lignan terameprocol inhibits the transcription of several inflammatory and oncogenic genes and has been evaluated for its anti-cancer properties. Here we investigated the effect of restricting the flexibility of the carbon linker connecting the terminal rings of terameprocol on its growth inhibitory activity. Conformational restriction was explored by introducing unsaturation, inserting polar entities with limited flexibility and cyclization of the connecting linker. Twenty three compounds were synthesized and evaluated on a panel of malignant human cells. The most promising compounds were those with non-polar linkers, as seen in butadiene 1a and the cyclized benzylideneindane analog 7. Both compounds were more potent than terameprocol on pancreatic BxPC-3 cells with GI50 values of 3.4 and 8.1μM, respectively. Selected isomers of 1a (E,E) and 7 (Z) adopted low energy bent conformations that mimicked the low energy conformer of terameprocol. It is tempting to propose that conformational similarity to terameprocol may have contributed to their good activity. The scaffolds of 1a and 7 should be further investigated for their anticancer potential.
    Bioorganic & medicinal chemistry letters 09/2013; DOI:10.1016/j.bmcl.2013.09.014 · 2.33 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A review of the state of the art gas turbine power plants designs with CO2 capture was performed to set up a list of technologies to be considered in a conceptual process superstructure. It has been found that the efficiency and economics of carbon dioxide capture in gas turbine combined cycle power plants can be remarkably improved by introducing Flue Gas Recirculation (FGR) so as to increase the CO2 concentration in the flue gas and to reduce the volume of the flue gas treated in a CO2 capture plant. Thus, this process was chosen as the main focus of the thermo-economic modeling and the combustion system related experimental testing.Combustion studies were performed to quantify the impact of reduced oxygen content (caused by flue gas recirculation) on combustion stability and emission characteristics (NOx, CO). Tests were performed with methane, methane/ethane (simulated natural gas), methane/hydrogen and natural gas (as distributed in Switzerland) at different FGR ratios. For all conditions the addition of ethane or hydrogen shows beneficial effects (restoration of flame reactivity) on flame stability and CO emission. Using PSI’s high pressure test rig, it has been shown, that by redirecting up to 30% of exhaust gas volume back to the combustor, the CO2 concentration in the exhaust can be increased to 8% vol. while keeping the flame temperature constant (Tad=1750K) and meeting the emission requirements (CO, NOx
    Energy Procedia 01/2011; 4:1901-1908. DOI:10.1016/j.egypro.2011.02.069

Full-text (2 Sources)

Available from
May 30, 2014